Influenza A virus-IN-19
Influenza A virus-IN-19 (Compound (S)-63) is an orally active, selective Influenza A virus inhibitor with an EC50 of 0.44 μM. Influenza A virus-IN-19 exhibits moderate binding affinity to Hemagglutinin, with a Kd of 5.66 μM. Influenza A virus-IN-19 inhibits trypsin-mediated cleavage of HA0, blocks the early viral entry process, and suppresses the replication of Influenza A virus. Influenza A virus-IN-19 improves the survival rate of mice in lethal influenza models. Influenza A virus-IN-19 can be used in studies related to Influenza A virus infection.
For research use only. We do not sell to patients.
- CAS No.: 3027187-19-2
- Formula: C16H14Cl2FNO3S
- Molecular Weight:390.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Influenza A virus-IN-19 potently inhibits influenza A virus H1N1 (A/FM/1/47) in MDCK cells, with an EC50 of 0.44 μM and a selectivity index of 210.75[1].
Influenza A virus-IN-19 potently inhibits oseltamivir (HY-13317)-resistant influenza A virus H1N1 (A/Tianjin Jinnan/15/2009) in MDCK cells, with an EC50 of 0.23 μM and a selectivity index of 403.17; it also inhibits influenza A virus H3N2 (A/HanFang/359/95), with an EC50 of 12.11 μM and a selectivity index of 5.51[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KM mice (female, 13−15 g, intranasally infected with 3 LD50 of mouse-adapted influenza virus A/Puerto Rico/8/1934)[1]
-
Dosage:5 mg/kg; 15 mg/kg; 45 mg/kg
-
Administration:p.o.; once pre-infection, then twice daily; 7 days
-
Result:Provided 0% survival at 5 mg/kg.
Achieved 20% survival at 15 mg/kg.
Resulted in 0% survival due to treatment-related toxicity at 45 mg/kg.
Caused progressive body weight loss across all treatment groups; surviving mice began to regain weight following treatment discontinuation.
Chemical Information
-
CAS No. 3027187-19-2
-
Molecular Weight 390.26
-
Formula C16H14Cl2FNO3S
-
SMILES
O=S(C1=C(C=C(C=C1)Cl)Cl)(N2CCO[C@H](C2)C3=C(C=CC=C3)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Influenza A virus-IN-19 Related Classifications
HY-182895 Related Classifications
Powered by Bioz